logo
Genetic study retraces the origins of coronaviruses in bats

Genetic study retraces the origins of coronaviruses in bats

Straits Times13-05-2025

The new study's researchers argue that the Covid-19 pandemic got its start at the Huanan Seafood Market in Wuhan, China. PHOTO: PIXABAY
WASHINGTON - In the early 2000s, a coronavirus infecting bats jumped into raccoon dogs and other wild mammals in south-western China. Some of those animals were sold in markets, where the coronavirus jumped again, into humans.
The result was the severe acute respiratory syndrome (Sars) pandemic, which spread to 33 countries and claimed 774 lives. A few months into it, scientists discovered the coronavirus in mammals known as palm civets sold in a market at the centre of the outbreak.
In a study published last week, a team of researchers compared the evolutionary story of Sars with that of Covid-19 some 17 years later.
The researchers analysed the genomes of the two coronaviruses that caused the pandemics, along with 248 related coronaviruses in bats and other mammals.
Dr Jonathan Pekar, an evolutionary virus expert at the University of Edinburgh in Scotland and an author of the new study, said that the histories of the two coronaviruses followed parallel paths.
'In my mind, they are extraordinarily similar,' he said.
In both cases, Dr Pekar and his colleagues argue, a coronavirus jumped from bats to wild mammals in south-western China. In a short period of time, wildlife traders took the infected animals hundreds of miles to city markets, and the virus wreaked havoc in humans.
'When you sell wildlife in the heart of cities, you're going to have a pandemic every so often,' said Dr Michael Worobey, an evolutionary biologist at the University of Arizona and an author of the new study.
The study lands at a fraught political moment.
In April , the White House created a webpage called Lab Leak: The True Origin of Covid-19, asserting that the pandemic had been caused not by a market spillover but by an accident in a lab in Wuhan, China.
Earlier in May , in its proposed budget, the White House described the lab leak as 'confirmed' and justified an US$18 billion (S$23 billion) cut to the National Institutes of Health in part on what it described as the agency's 'inability to prove that its grants to the Wuhan Institute of Virology were not complicit in such a possible leak'.
The Chinese government responded with a flat denial that the pandemic had been caused by a Wuhan lab leak and raised the possibility that the virus had come instead from a biodefence lab in the United States.
'A thorough and in-depth investigation into the origins of the virus should be conducted in the US,' the statement read.
Dr Sergei Pond, a virus expert at Temple University, said that he did not consider the origin of Covid-19 settled. But he worried that the incendiary language from the two governments would make it difficult for scientists to investigate – and debate – the origin of Covid-19.
'If it wasn't tragic, you'd have to laugh; it's so farcical,' Dr Pond said.
In the first weeks of the Covid-19 pandemic in early 2020, claims circulated that the virus responsible was a biological weapon created by the Chinese army. A group of scientists who analysed the data available at the time rejected that idea.
Although they could not rule out an accidental lab leak, they favoured a natural origin of Covid-19.
As Dr Worobey and other scientists started studying the origin of Covid-19, US intelligence agencies were also assessing it. Their assessments have been mixed.
The FBI favoured an escape from the Wuhan Institute of Virology with moderate confidence; the CIA reached the same assessment, with only low confidence. The Energy Department leans with low confidence to the virus escaping from a different lab in Wuhan. Other agencies lean towards a natural origin.
The agencies have not made their evidence or their analyses public, so scientists cannot evaluate the basis of their conclusions.
However, Dr Worobey and other researchers have published a string of papers in scientific journals. Along the way, Dr Worobey became convinced that the Covid-19 pandemic had started at the Huanan Seafood Market in Wuhan.
'Scientifically, it's as clear as HIV or Spanish flu,' Dr Worobey said, referring to two diseases whose origins he has also studied.
For the new study, Dr Worobey, Dr Pekar and their colleagues compared the genomes of 250 coronaviruses, using their genetic similarities and differences to determine their relationships. They were able to reconstruct the history of the coronaviruses that cause both Sars and Covid-19 – known as Sars-CoV and Sars-CoV-2.
The ancestors of both viruses circulated in bats across much of China and neighbouring countries for hundreds of thousands of years. In the last 50 years or so, their direct ancestors infected bats that lived in south-western China and northern Laos.
As the coronaviruses infected the bats, they sometimes ended up inside a cell with another coronavirus. When the cell made new viruses, it accidentally created hybrids that carried genetic material from both of the original coronaviruses – a process known as recombination.
'These aren't ancient events,' said Dr David Rasmussen , a virus expert at North Carolina State University not involved in the new study. 'These things are happening all the time. These viruses are truly mosaics.'
In 2001, just a year before the Sars pandemic started in the city of Guangzhou, the researchers found, Sars-CoV underwent its last genetic mixing in bats.
Only after that last recombination could the virus have evolved into a human pathogen. And since Guangzhou is several hundred miles from the ancestral region of Sars-CoV, bats would not have been able to bring the virus to the city in so little time.
Instead, researchers generally agree, the ancestors of Sars-CoV infected wild mammals were later sold in markets around Guangzhou. A few months after the start of the Sars pandemic, researchers discovered Sars-CoV in palm civets and other wild mammals for sale in markets.
The researchers found a similar pattern when they turned to Sars-CoV-2, the cause of Covid-19. The last recombination in bats took place between 2012 and 2014, just five to seven years before the Covid-19 pandemic, several hundred miles to the north-east, in Wuhan.
That was also a substantial departure from the region where the virus' ancestors had circulated. But it was comparable to the journey that Sars-CoV took, courtesy of the wildlife trade.
Proponents of lab-leak theories have highlighted the long distance between Wuhan and the locations where the closest relatives of Sars-CoV-2 have been found. If bats could not fly to the region around Wuhan and infect wild mammals there, they maintain, then scientists must have collected the coronavirus from bats in south-west China and tinkered with it in their lab, from which it then escaped.
American scientists have criticised the Wuhan Institute of Virology for lax safeguards in their coronavirus experiments. But no one has offered evidence that the progenitor of Sars-CoV-2 was at the Wuhan Institute of Virology before the pandemic.
The new study by Dr Worobey and his colleagues shows that bat coronaviruses can travel long distances without the help of scientists, through the wildlife trade.
The researchers argue that these findings agree with studies that they published in 2022, which pointed to the Huanan Seafood Market in Wuhan as the place where the Covid-19 pandemic got its start.
Wild mammals were sold there, many early cases of Covid-19 were recorded there, and Chinese researchers collected different strains of Sars-CoV-2 carrying distinct mutations there.
Dr Worobey and his colleagues argued that the virus had twice spilled over from wild mammals at the market.
Dr Marc Eloit, the former director of the Pathogen Discovery Laboratory at Pasteur Institute in Paris, said that the new study was significant for providing a clear picture of where Sars-CoV-2 came from.
But he also observed that the coronavirus was markedly different from its closest known relatives in bats. After it split from those viruses, it must have mutated or undergone recombination to become well adapted for spreading in humans.
'I maintain that the possibility of a recombination event – whether accidental or deliberate – in a laboratory setting remains just as plausible as the hypothesis of emergence via an intermediate host on the market,' Dr Eloit said.
Dr Eloit and other scientists agreed that finding an intermediate form of Sars-CoV-2 in a wild mammal would make a compelling case for a natural spillover. Chinese authorities looked at some animals at the start of the pandemic and did not find the virus in them.
However, wildlife vendors at the Huanan market removed their animals from the stalls before scientists could study them. And once China put a stop to wildlife sales, farmers culled their animals.
'There's a big missing piece, and you really can't dance around it,' Dr Pond said. NYTIMES
Join ST's Telegram channel and get the latest breaking news delivered to you.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gaza ministry says Israel kills more than 30 aid seekers, Israel denies, World News
Gaza ministry says Israel kills more than 30 aid seekers, Israel denies, World News

AsiaOne

time6 hours ago

  • AsiaOne

Gaza ministry says Israel kills more than 30 aid seekers, Israel denies, World News

CAIRO/GAZA — More than 30 Palestinians were killed and nearly 170 injured on Sunday (June 1) in south Gaza near a food distribution site, the health ministry said, as witnesses reported Israeli soldiers fired on people trying to collect aid and Israel denied it. The US-based Gaza Humanitarian Foundation (GHF) said food was handed out without incident on Sunday at the distribution point in Rafah and there were no deaths or injuries. GHF released undated video to support its statement that showed dozens of people gathering around piles of boxes. Reuters could not independently verify the video or what took place. Witnesses said the Israeli military opened fire as thousands of Palestinians gathered to receive food aid. Israel's military said that an initial inquiry found soldiers had not fired on civilians while they were near or within the distribution site. The Hamas-controlled Gaza health ministry said 31 people were killed with a single gunshot wound to the head or chest from Israeli fire as they were gathered in the Al-Alam district aid distribution area in Rafah. It said 169 were injured. In addition to Israeli gunshots, residents and medics said an Israeli tank had opened fire at thousands of people en route to the Rafah site. The International Committee of the Red Cross (ICRC) said its field hospital in Rafah received 179 casualties, most with gunshot or shrapnel wounds. "All patients said they had been trying to reach an aid distribution site. This is the highest number of weapon-wounded in a single incident since the establishment of the field hospital over a year ago," ICRC said. The United Nations has said most of Gaza's 2 million population is at risk of famine after an 11-week Israeli blockade on aid entering the strip. The Gaza Humanitarian Foundation launched its first distribution sites last week and said it would launch more. The Israeli military has said GHF had established four sites so far. The organisation's aid plan, which bypasses traditional aid groups, has come under fierce criticism from the United Nations and humanitarian organisations which say GHF does not follow humanitarian principles. There were chaotic scenes as hungry Gazans rushed its sites last last week. Hamas reported deaths and injuries in the tumult, and Israel said its troops fired warning shots. Because the GHF distribution points are few and all in south Gaza, UN officials have said its plans force Palestinians, especially in the north, to relocate and face unsafe conditions. Philippe Lazzarini, head of the UN's Palestinian relief agency, condemned Sunday's deaths and said in a statement on X that "aid distribution has become a death trap". The Hamas-run Gaza government media office accused Israel of using aid as a weapon, "employed to exploit starving civilians and forcibly gather them at exposed killing zones, which are managed and monitored by the Israeli military". At Nasser Hospital in nearby Khan Younis city where some casualties were brought, Gaza paramedic Abu Tareq said there was "a tragic situation in this place. I advise them that nobody goes to aid delivery points". Israel denies that people in Gaza are starving because of its actions, saying it is facilitating aid deliveries and pointing to its endorsement of the new GHF distribution centres and its consent for other aid trucks to enter Gaza. US President Donald Trump said last month that a lot of people in Gaza were "starving". Israel accuses Hamas of stealing supplies intended for civilians and using them to entrench its hold on Gaza. Hamas denies looting supplies and has executed a number of suspected looters. Reda Abu Jazar said her brother was killed as he waited to collect food near the Rafah aid distribution centre. "Let them stop these massacres, stop this genocide. They are killing us," she said, as Palestinian men gathered for funeral prayers. The Red Crescent reported that 14 Palestinians were injured on Sunday near a separate GHF aid site in central Gaza. Ceasefire talks later Israel and Hamas meanwhile traded blame for the faltering of a new Arab and US mediation bid to secure a temporary ceasefire and the release of Israeli hostages held in Gaza by Hamas, in exchange for Palestinians in Israeli jails. Hamas said on Saturday it was seeking amendments to a US-backed ceasefire proposal, but Trump's envoy Steve Witkoff rejected the group's response as "totally unacceptable". Egypt and Qatar said in a joint statement that they are continuing efforts to overcome disagreements and reach a ceasefire. Hamas on Sunday welcomed those efforts and expressed its readiness to start a round of indirect negotiations immediately to reach an agreement, the group said on Sunday in a statement. Israel began its offensive in Gaza in response to the Hamas-led attack on southern Israel on Oct 7, 2023, which killed 1,200 people, mostly civilians, according to Israeli tallies, and saw 251 taken as hostages into Gaza. Israel's campaign has devastated much of Gaza, killing more than 54,000 Palestinians and destroying most buildings. Much of the population now lives in shelters in makeshift camps. [[nid:718414]]

Protect workers from heat waves or face fines, Japan tells firms
Protect workers from heat waves or face fines, Japan tells firms

Straits Times

time7 hours ago

  • Straits Times

Protect workers from heat waves or face fines, Japan tells firms

TOKYO - Tougher rules being enforced in Japan will see employers fined if they fail to take adequate precautions to protect workers from extreme temperatures. The revised legislation, which came into effect on June 1, is a rare global example of a national-level policy on heat safety for employees, and comes after 30 workplace deaths and roughly 1,200 injuries last year associated with high temperatures, according to health ministry data. Most of those affected worked in construction or manufacturing. Japan's government moved to strengthen protections following last summer's searing heat – which included the highest July temperatures on record, the ministry said in a statement. Businesses will face potential penalties including fines of ¥500,000 (S$4,500) if provisions are not sufficient. Heatstroke is a potentially life-threatening condition caused by dangerously high body temperature that can result in severe organ damage if not treated quickly. There were almost half a million heat-related deaths annually between 2000 and 2019, according to a report last year by the World Health Organisation (WHO). Along with public health impacts, higher temperatures can impact worker productivity and there's growing concern about the economic toll that heat waves have on economies. Global average temperatures exceeded 1.5 deg C above pre-industrial levels for the first time in 2024 and new highs are forecast to be recorded over the next five years, according the World Meteorological Organisation. Japan's legislation requires employers to implement protocols to quickly spot and aid workers showing symptoms of heatstroke. Policies encourage companies to use a buddy system at work sites, distribute wearable devices to monitor staff, and provide emergency transportation to hospitals or clinics. Employers are urged to monitor the Wet Bulb Globe Temperature index, a gauge of heat stress in direct sunlight that takes into account factors like temperature and humidity. Specific measures are required for work sites where the index value exceeds 28 deg C or an atmospheric temperature of 31 deg C for more than one hour, or for a total of four hours or more in a single day. A worker performing moderate work intensity loses half of their work capacity at 33 deg C to 34 deg C, according to a 2019 study from the International Labour Organisation. The same report estimated the economic impact of heat stress by 2030 at US$2.4 trillion (S$3.1 trillion) if greenhouse gas emissions aren't cut. 'We are working on measures such as taking breaks according to the heat index and measuring internal body temperature using wearable devices,' said a spokesperson for Shimizu Corp, one of the nation's largest general contractors, which employs more than 20,000 people. The company said it is constantly updating its heatstroke policies. Parcel delivery service Yamato Transport Company plans to distribute 75,000 fan-equipped vests to workers, including those who use carts and bicycles to drop off packages. It is also installing 3,000 wet bulb index measuring devices at business locations to better track working conditions. The measures are not in response to the new law, the company said. California and Washington are among US states to have developed similar rules on worker protections, and the US Occupational Safety and Health Administration has proposed setting a federal standard. There were an average 40 recorded fatalities a year in the US related to environmental heat between 2011 and 2020, according to the Department of Labor. BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you.

Mirxes, Singapore's billion-dollar biotech firm led by life sciences scholar Zhou Lihan, lists in Hong Kong
Mirxes, Singapore's billion-dollar biotech firm led by life sciences scholar Zhou Lihan, lists in Hong Kong

Straits Times

time10 hours ago

  • Straits Times

Mirxes, Singapore's billion-dollar biotech firm led by life sciences scholar Zhou Lihan, lists in Hong Kong

Mirxes CEO Dr Zhou Lihan, his wife Yeap Su Phing, parents and two children at the Hong Kong Stock Exchange in Central after the Singapore biotech firm launched its IPO on May 23. PHOTO: MIRXES – Singapore has produced its first billion-dollar biotechnology start-up, 25 years after it began formally building its life sciences industry. Mirxes, which invented and produces the world's first blood test kit to detect early stage gastric cancer, is helmed by Dr Zhou Lihan, a naturalised Singaporean from the country's maiden batch of life sciences graduates. He arrived on the Lion City's shores as a wide-eyed 15-year-old PRC (People's Republic of China) scholar, navigating life and studies in a foreign country. Today, the 42-year-old is chief executive officer and co-founder of Mirxes (pronounced 'm'raek'sis'). It is the first South-east Asian biotech start-up to achieve a valuation of more than US$1 billion (S$1.29 billion), when on May 23 it launched its initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX). The company's market capitalisation is HK$8.29 billion, or US$1.06 billion. It has been trading around HK$30 per share, up 28 per cent from its listing price of HK$23.30. It is also South-east Asia's first biotech firm to list on HKEX. The microRNA-based cancer-detection start-up, which was spun out of Singapore's public sector R&D agency A*Star in 2014, has yet to become a household name in the country. But it is already a big player in the regional biotech industry. Now, the company has reached a critical level in its development where it can build on its success only by leveraging on an expansive fund-raising platform with a mature base of investors familiar with the industry. That is why, instead of listing in Singapore, Mirxes opted to do so first in Hong Kong, Dr Zhou told The Straits Times. He does not, however, discount the possibility of Mirxes listing in Singapore eventually. Dr Zhou's life story in the Republic tracks closely with some of the country's strategic economic policies over the years. 'I left China in 1998 after learning, through the Suzhou-Singapore Industrial Park project, about the opportunity to take on a scholarship to come to Singapore,' the Suzhou-born Dr Zhou told ST in an unmistakably Singaporean accent. Dr Zhou (second from left) with his fellow PRC scholars studying in Singapore's Anglican High School in 1998. PHOTO: COURTESY OF ZHOU LIHAN The project was launched in 1994 for China to adapt the Republic's development experiences to its own context, and for Singapore to develop an external wing to its economy. The PRC scholarship system is a Singapore Government-sponsored scheme for top Chinese teenage students since the 1990s, aimed at having them eventually contribute to economic development and potentially set down roots in the country . Finding love at NUS After going through the local education system at Anglican High School and Temasek Junior College, Dr Zhou enrolled at the National University of Singapore (NUS) in 2003, among the first batch of life sciences students. The life sciences programme was introduced as part of a government initiative in 2000 to develop the Republic into a regional biomedical hub. 'Because I spent most of my formative years in Singapore, all my friends and family are in Singapore. I even met my wife in NUS on shuttle bus A2, heading from the arts faculty to (university hostel) Prince George's Park,' Dr Zhou recalled with a laugh. Dr Zhou (top row, second from left), with Associate Professor Too Heng-Phon (far right) and fellow researchers from Prof Too's lab during their university days in 2008. PHOTO: COURTESY OF ZHOU LIHAN His wife, a Malaysian-born Singaporean, was an NUS arts student whom he got to know better in the students' union , he explained. They have a son and a daughter, aged eight and three, respectively. The family, including Dr Zhou's parents who have also moved from Suzhou to Singapore , were at HKEX in the central business district to witness Mirxes' IPO launch on May 23. Mirxes' history dates back to Dr Zhou's days at NUS, where he obtained his PhD in biochemistry and molecular biology at the Yong Loo Lin School of Medicine in 2012. During his PhD studies, he, fellow scientist Zou Ruiyang and their mentor, Associate Professor Too Heng-Phon, developed the technology to detect microRNA (micro ribonucleic acid), the smallest genetic material ever found in living things. Dr Zhou with his mentor, Prof Too, on his graduation day in 2007. PHOTO: COURTESY OF ZHOU LIHAN Their research, which the trio took with them to A*Star when they joined the agency in 2010, proved so ground-breaking that they set up an enterprise three years later with the agency's support and a government grant to commercialise their technology. Thus, Mirxes was born: a three-person start-up with Dr Zhou as CEO, Dr Zou as chief technology officer, and Prof Too as chief scientific adviser, aimed at developing an accurate, affordable and easily accessible early detection system for various cancers and other diseases. In the decade since, Mirxes has grown into a 350-strong company with a presence in China, Japan, Malaysia, the Philippines and the United States, and partnerships with global biotech giants including Johnson & Johnson and Pfizer. Dr Zhou (left) and Mirxes' co-founder, Dr Zou Ruiyang, at the biotech startup in the initial years after it spun off from A*Star. PHOTO: MIRXES The firm's flagship invention, GastroClear, in 2019 became the world's first molecular blood test approved for early detection of gastric cancer in high-risk populations. It was developed in close collaboration with the Singapore Gastric Cancer Consortium. The test – available in Singapore for less than $150 at public hospitals or around $250 in private clinics – is less expensive and invasive than an endoscopy, the traditional diagnostic procedure for stomach cancer, which can cost between $400 and $3,000. GastroClear has an 87 per cent accuracy, better than any other blood-based tests for the detection of gastric cancer. Patients who test positive are recommended to undergo an endoscopy for more specific results. The test is less expensive and invasive than an endoscopy, the traditional diagnostic procedure for stomach cancer, which can cost between $400 and $3,000. PHOTO: NATIONAL UNIVERSITY HEALTH SYSTEM Listing in Hong Kong Months of careful consideration preceded Mirxes' decision to list in Hong Kong over Singapore. Ultimately, it came down to two key factors. 'Firstly, our flagship product GastroClear is focused on stomach cancer, a very Asian disease,' Dr Zhou said. 'China alone accounts for half of all stomach cancer cases worldwide.' The Hong Kong platform provides a gateway into mainland China, the biggest market not just for stomach cancer tests, but also for the scale and speed of cancer clinical trials to accelerate the firm's research and development efforts. 'So listing in (the Chinese territory of) Hong Kong makes sense, because the investors here will understand our product's value to them.' Secondly, he added, HKEX's dedicated biotech listing regime has built up an investor base that 'understands how to look at biotech firms' financials without getting scared off'. Mirxes is still in the red, reporting net losses exceeding US$92 million for 2024 – 30 per cent more than the previous year. It is already generating revenue, although the US$20 million it reported for 2024 is a 16 per cent drop from that in 2023. 'People get worried that Mirxes is losing money,' Dr Zhou said. 'But if we want to be competitive globally, we have to invest in R&D and innovation. But that's something that our South-east Asian investor base is not yet familiar with.' HKEX's investors, on the other hand, are no strangers to promising yet still-loss-making start-ups. Hong Kong in 2018 started allowing yet-to-be-profitable biotech firms to list on its main board under the exchange's Chapter 18A regulations, to attract companies in cutting-edge industries. Since then, more than 70 such firms – which would otherwise not have qualified to list – have launched their IPOs in the city, gaining access to much-needed funds to grow their fledgling technologies and innovations . Mirxes CEO Dr Zhou Lihan (right) with a Hong Kong Stock Exchange representative at the IPO ceremony in Hong Kong on May 23. PHOTO: MIRXES The 18A rules recognise these start-ups' potential for growth, granting them access to capital as long as they have one core product past the concept phase, HK$1.5 billion in expected market value, and two years of financial records, among other criteria. In Asia, biotech start-ups that have yet to bring in revenue can also choose to list on subsidiary boards that cater to such firms, like China's ChiNext, Singapore's Catalist and Korea's Kosdaq. But the drawbacks include lower trading volumes and hence lower funding , and less visibility . Rebuilding ties in China HKEX's listing reforms, like Chapter 18A, have over the years opened new pathways for a broader range of companies around the world to raise funds in the city. It is on track to be the world's top IPO destination by the end of 2025, according to Swiss investment bank UBS. Its IPO market has raised HK$76 billion so far in 2025, more than seven times that in the same period a year ago, Financial Secretary Paul Chan said on May 25. The city is further cementing its status as a leading fund-raising hub for the tech and biotech sectors. In early May, it set up a scheme to streamline the IPO process for such firms, offering them 'a more efficient pathway' to listing and allowing them to file confidentially to avoid drawing competitors' attention. But some companies seeking a Hong Kong listing may still face a lengthy approval process from the China Securities Regulatory Commission, under rules introduced in March 2023 that also pertain to firms with principal business operations in mainland China. Mirxes, which has laboratories in Hangzhou, filed to list in Hong Kong in July 2023. One of Mirxes' laboratories in Singapore. It has a presence in China, Japan, Malaysia, the Philippines and the United States. PHOTO: MIRXES Dr Zhou said that while his China background is 'definitely helpful' in bringing Mirxes to the world's second-biggest economy, 'honestly, I had to rebuild all my connections there as I had left China as a secondary school student'. These days, he is a 'weekend dad', travelling around mainland China, Hong Kong and South-east Asia for work and seeing his family in Singapore only on weekends. 'Most people – my parents included – will not be able to fully comprehend the technical details of what we do at Mirxes,' Dr Zhou said. The firm will allocate some of its IPO funds to promote awareness and the use of GastroClear in China and South-east Asia. The cash will also fund ongoing research into its colorectal and multi-cancer detection tests, among other plans. Reflecting on Mirxes' journey from fledgling start-up to IPO, Dr Zhou said the listing 'would not have been possible without the Singapore Government's strong support and consistent investment in life sciences over the years'. 'It proves a point that our Singapore technologies and companies are as good, if not better, than others,' he said. 'But we tend to be a little too humble, and not as patient .' The vibrant ecosystem of biotech firms in Boston or San Francisco, for example, was built up over 50 years, the CEO noted. 'In Singapore, we started only some 20 years ago … We are reaching a point where we should see more companies like Mirxes taking their next steps .' Dr Zhou hopes Mirxes' IPO will go a long way in enhancing the company's global credibility. 'If the public sees that this biotech firm has been vetted, has gone public, and everything about it is transparent and fully disclosed, that will add a layer of trust,' he said. 'And in the healthcare business, trust is very important.' Magdalene Fung is The Straits Times' Hong Kong correspondent. She is a Singaporean who has spent about a decade living and working in Hong Kong. Join ST's Telegram channel and get the latest breaking news delivered to you.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store